VKTX
New money, not exactly new love
Viking Therapeutics woke up Thursday and basically said, “We’d like more cash, please.” The company priced a concurrent offering of 7.85 million shares at $35 each, plus $225 million of 2% convertible senior notes due 2032. Translation: the pipeline gets a bigger war chest, but existing shareholders get a fresh dilution headache.
Why investors are side-eyeing it
The market wasn’t exactly sending flowers. Shares were down more than 15% as traders digested the bigger financing and adjusted for the fact that more stock in the wild usually means your slice of the pie gets thinner.
Viking says the money will go toward the continued development, advancement, and commercialization of VK2735 and VK3019, along with general R&D and working capital. In other words: keep the obesity-drug machine running and hope the science keeps the story interesting.
The annoying part of good news
Financing can be a necessary evil, especially for a clinical-stage biotech with expensive trials and even pricier ambitions. But for now, the tape is telling a simpler story: when a company raises a big pile of money, the stock often has to do a little math homework first.
Big picture: Viking gets runway, but investors are paying for it today in the form of a bruised share price and a louder dilution debate.